HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Gastrointestinal stromal tumor — Clinical Guidelines

Overview

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, characterized by mutations in KIT or PDGFRA genes, leading to variable aggressiveness and clinical behavior. 1 5 22

Diagnosis

Imaging: Contrast-enhanced CT, MRI, and endoscopic ultrasound for initial detection and staging. 1 7

Biopsy and Histopathology: Essential for definitive diagnosis; KIT and PDGFRA mutation analysis recommended. 1 19 7

Risk Stratification: Based on tumor size, location, mitotic rate, and mutational status (e.g., high-risk features include size >5 cm, mitotic rate >5/50 HPFs, and specific KIT/PDGFRA mutations). 1 5 19

Molecular Testing: Essential for guiding targeted therapy; includes sequencing for KIT and PDGFRA mutations. 1 19 21

Management

First-Line Treatment:

- Tyrosine Kinase Inhibitors (TKIs): Imatinib as first-line therapy for unresectable or metastatic disease; dose typically 400-800 mg/day. 1 5 17 - Surgical Resection: Primary treatment for localized, resectable GISTs with negative margins. 1 8 9

Adjunctive Treatments:

- Second-Line TKIs: Sunitinib, regorafenib for imatinib-resistant or intolerant patients. 12 16 - Interventional Radiology: Radiofrequency ablation (RFA) for local control of residual disease or metastases. 20

Follow-Up: Regular imaging and biomarker monitoring to detect recurrence or resistance. 1

Special Populations

Elderly Patients: Consider comorbidities and functional status when selecting treatment modalities; TKIs may require dose adjustments. 15

Comorbidities: Management of concurrent conditions like renal impairment when prescribing TKIs like sunitinib or imatinib. 16

Key Recommendations

Perform comprehensive molecular testing including KIT and PDGFRA mutations for risk stratification and guiding targeted therapy (Evidence: Strong 1 19).

Use imatinib as first-line therapy for unresectable or metastatic GIST (Evidence: Strong 1 5).

Consider surgical resection for localized GISTs with negative margins when feasible (Evidence: Strong 1 8).

Implement regular follow-up with imaging and biomarker assessment to monitor disease progression and resistance (Evidence: Moderate 1).

Evaluate elderly patients and those with comorbidities carefully to tailor TKI therapy appropriately (Evidence: Moderate 15).

References

1 Judson I, Jones RL, Wong NACS, Dileo P, Bulusu R, Smith M et al.. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. British journal of cancer 2025. link 2 Yamaguchi D, Otake R, Tada T, Nakayama K, Urazumi K, Kono K. [A Case of Intraperitoneal Gastrointestinal Stromal Tumor with Pedicle Torsion Requiring Emergency Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy 2025. link 3 Ikota M, Akahoshi T, Murata I, Adikrisna R, Ohta T, Kitasato K et al.. [Perforation of Small Intestinal Gastrointestinal Stromal Tumor Required Emergency Surgery-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy 2025. link 4 Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H et al.. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International journal of clinical oncology 2024. link 5 Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez-García J, Martínez-Marín V et al.. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023. link 6 Seyam R, Chaer KA, Abouelkhair A, Almouh A, Alzahrani O, Sayed AG et al.. The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review. Scientific reports 2023. link 7 Hornick JL, Webster F, Dei Tos AP, Hemmings C, Miettinen M, Oda Y et al.. Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2023. link 8 Chetta N, Martines G, Picciariello A, Capuano P. Successful Laparoscopic Sleeve Gastrectomy in Emergency for a Gastric Gastrointestinal Stomal Tumor (GIST) with Acute Bleeding: A Case Report. The American journal of case reports 2018. link 9 Janczak D, Rać J, Pawłowski W, Dorobisz T, Ziomek A, Janczak D et al.. Management of gastrointestinal stromal tumors: A 10-year experience of a single surgical department. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2018. link 10 Shi SS, Wu N, He Y, Wei X, Xia QY, Wang X et al.. EGFR gene mutation in gastrointestinal stromal tumours. Histopathology 2017. link 11 Gleeson FC, Kerr SE, Kipp BR, Voss JS, Minot DM, Tu ZJ et al.. Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent. Gastrointestinal endoscopy 2016. link 12 . Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects. Prescrire international 2015. link 13 Lu J, Lu X, Jiao T, Zheng M. Endoscopic management of upper gastrointestinal submucosal tumors arising from muscularis propria. Journal of clinical gastroenterology 2014. link 14 Chen YT, Sun HL, Luo JH, Ni JY, Chen D, Jiang XY et al.. Interventional digital subtraction angiography for small bowel gastrointestinal stromal tumors with bleeding. World journal of gastroenterology 2014. link 15 Blay JY, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer treatment reviews 2014. link 16 Szałek E, Karbownik A, Grabowski T, Sobańska K, Wolc A, Grześkowiak E. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model. Pharmacological reports : PR 2013. link71497-x) 17 Judson I. Therapeutic drug monitoring of imatinib--new data strengthen the case. Clinical cancer research : an official journal of the American Association for Cancer Research 2012. link 18 Faigel DO, Abulhawa S. Gastrointestinal stromal tumors: the role of the gastroenterologist in diagnosis and risk stratification. Journal of clinical gastroenterology 2012. link 19 Barreca A, Fornari A, Bonello L, Tondat F, Chiusa L, Lista P et al.. KIT and PDGFRA mutations and PDGFRA immunostaining in gastrointestinal stromal tumors. Molecular medicine reports 2011. link 20 Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematology/oncology clinics of North America 2009. link 21 Elshenawy YM, Ganote CE, Al-Abbadi MA. Fatal abdominal sarcomatosis secondary to gastrointestinal stromal tumor with bland histology. Saudi medical journal 2009. link 22 Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008. link 23 Wu TJ, Lee LY, Yeh CN, Wu PY, Chao TC, Hwang TL et al.. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC gastroenterology 2006. link 24 Peters O, Devis G. The laser and the lower gastrointestinal tract. Journal belge de radiologie 1989. link 25 Wani NA, Shah IA, Koul V. Leiomyoblastoma stomach. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 1989. link

Gastrointestinal stromal tumor